A meaningful prediction of functional decline in amyotrophic lateral sclerosis based on multi-event survival analysis

TL;DR

This paper introduces a novel multi-event survival analysis method to predict functional decline in ALS patients, enabling personalized prognosis and treatment planning based on individual covariates.

Contribution

The study presents a new covariate-based multi-event survival model for ALS that outperforms traditional estimators and allows for counterfactual predictions of disease progression.

Findings

Covariate-based models outperform Kaplan-Meier in predicting ALS functional decline.

The method enables personalized risk assessment and counterfactual analysis.

Riluzole shows minimal impact on predicted functional decline.

Abstract

Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of the motor neurons that causes progressive paralysis in patients. Current treatment options aim to prolong survival and improve quality of life. However, due to the heterogeneity of the disease, it is often difficult to determine the optimal time for potential therapies or medical interventions. In this study, we propose a novel method to predict the time until a patient with ALS experiences significant functional impairment (ALSFRS-R <= 2) for each of five common functions: speaking, swallowing, handwriting, walking, and breathing. We formulate this task as a multi-event survival problem and validate our approach in the PRO-ACT dataset (N = 3220) by training five covariate-based survival models to estimate the probability of each event over the 500 days following the baseline visit. We then predict five event-specific individual survival distributions (ISDs) for a patient, each providing an interpretable estimate of when that event is likely to occur. The results show that covariate-based models are superior to the Kaplan-Meier estimator at predicting time-to-event outcomes in the PRO-ACT dataset. Additionally, our method enables practitioners to make individual counterfactual predictions -- where certain covariates can be changed -- to estimate their effect on the predicted outcome. In this regard, we find that Riluzole has little or no impact on predicted functional decline. However, for patients with bulbar-onset ALS, our model predicts significantly shorter time-to-event estimates for loss of speech and swallowing function compared to patients with limb-onset ALS (log-rank p<0.001, Bonferroni-adjusted alpha=0.01). The proposed method can be applied to current clinical examination data to assess the risk of functional decline and thus allow more personalized treatment planning.